Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib in High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT05128825Phase 2Recruiting
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of azenosertib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by Zentalis Pharmaceuticals. Primary endpoint: Objective Response Rate at 12 months. Started Feb 2022; status: recruiting.
02
Drugs
azenosertib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05128825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128825.